# A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Study · id `cardio:ct-nct03988920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03988920](<https://clinicaltrials.gov/study/NCT03988920>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03988920

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

## Technical summary

Registry record NCT03988920. Non-randomized; no masking; primary purpose treatment. Start 2019-06-15 (actual); primary completion 2021-06-26 (actual). Results posted on 2023-03-29.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 172 participants (enrolled count; ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Started: 2019-06-15 (actual) (ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Primary completion: 2021-06-26 (actual) (ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Completion: 2021-07-31 (actual) (ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Results first posted: 2023-03-29 (ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03988920, source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03988920-2023-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Acronym: NORMALIZE
- Condition: Hyperphosphatemia
- Condition: End Stage Renal Disease
- Intervention (Drug): Tenapanor
- Intervention (Drug): Sevelamer Carbonate
- Lead sponsor: Ardelyx
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Ardelyx (`cardio:org-ardelyx`)

## Provenance

Content hash: d4bf2a49f577a5bf67f38bf8c6eb5b6e167b0a5616c1ec95fa071dc412253b1e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
